|Bid||0.0990 x 0|
|Ask||0.1000 x 0|
|Day's range||0.0990 - 0.1020|
|52-week range||0.0220 - 0.1450|
|Beta (5Y monthly)||1.19|
|PE ratio (TTM)||N/A|
|Earnings date||20 Oct 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
We can readily understand why investors are attracted to unprofitable companies. For example, Prescient Therapeutics...
This article will reflect on the compensation paid to Yatomi-Clarke Lee who has served as CEO of Prescient...
In 2016, Yatomi-Clarke Lee was appointed CEO of Prescient Therapeutics Limited (ASX:PTX). First, this article will...